KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

Thiam Souleymane; Dia Fatou Kine Sy Thorpe; Sambiani Damigou Mawuli; Diop Papa Saloum; Ka Ibrahima; Deguenonvo Gabriel Nougnignon Comlan; Ndiaye Yaye Dié; Cisse Fatou; Ndiaye Arame; Samba Abdourahmane; Coly Najah Fatou; Soumah Idrissa Yaya; Diedhiou Fatou; Agossou Hortence Honorine Médécé; Gaye Amy; Ndiaye Tolla; Dial Cherif Mouhame; Ndiaye Daouda; Diallo Fatou

doi:doi:10.11648/j.ijgg.20221001.16

KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal

Thiam Souleymane, Dia Fatou Kine Sy Thorpe, Sambiani Damigou Mawuli, Diop Papa Saloum, Ka Ibrahima, Deguenonvo Gabriel Nougnignon Comlan, Ndiaye Yaye Dié, Cisse Fatou, Ndiaye Arame, Samba Abdourahmane, Coly Najah Fatou, Soumah Idrissa Yaya, Diedhiou Fatou, Agossou Hortence Honorine Médécé, Gaye Amy, Ndiaye Tolla, Dial Cherif Mouhame, Ndiaye Daouda, Diallo Fatou

Published in International Journal of Genetics and Genomics (Volume 10, Issue 1)

Received: 8 February 2022 Accepted: 1 March 2022 Published: 9 March 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV is endemic. The objective of our study was to determine the prevalence of KRAS and BRAF mutations in patients with HCC. Mutations in codons 12 and 13 of KRAS and the V600E mutation of the BRAF gene were searched by HRM on Light Cycler 480 and confirmed by direct sequencing. A total of 34 HCC patients underwent molecular testing for codon 12 and 13 mutations in the KRAS gene and the V600E mutation in the BRAF gene. Melting curve analysis showed a prevalence of 23.5% (n=8/34) for the KRAS gene and 41.2% (n=14/34) for the BRAF gene. The mean age of BRAF mutation carriers was lower compared with KRAS mutation carriers. Chronic HBV carriage appeared to play a role in the development of these mutations, increasing the risk by 2 (CI(95)=0.55-7.24; p=0.395) for BRAF and by 1.78 (CI(95)=0.23-13.5; p=1) for KRAS. KRAS and BRAF mutations do not appear to play a role in tumor metastasis. However, these results need to be confirmed by further studies with a larger sample size. Alterations in the RAS/RAF/MAP Kinase pathway appear to be more prominent in HBV-induced HCC. This may hinder management with receptor tyrosine kinase inhibitors, the basis for treatment of advanced HCC.

Published in	International Journal of Genetics and Genomics (Volume 10, Issue 1)
DOI	10.11648/j.ijgg.20221001.16
Page(s)	37-42
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

KRAS, V600E BRAF, HBV, Hepatocellular Carcinoma, Senegal

References

[1]	Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71 (3), 209-249.
[2]	IARC-TP53 Database, “IARC TP53 Database.” https://p53.iarc.fr/ (accessed Nov. 22, 2021).
[3]	Harding, J. J., Nandakumar, S., Armenia, J., Khalil, D. N., Albano, M., Ly, M.,... & Abou-Alfa, G. K. (2019). Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clinical Cancer Research, 25 (7), 2116-2126.
[4]	Smela, M. E., Currier, S. S., Bailey, E. A., & Essigmann, J. M. (2001). The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis. Carcinogenesis, 22 (4), 535-545.
[5]	RJ, B. M. S. (2004). The enigmatic X gene of hepatitis B virus J. Virol. 781272512734. Bouchard, MJ, and Schneider, RJ (2004). The enigmatic X gene of hepatitis B virus. J. Virol, 78, 12725-12734.
[6]	Thiam, S., Diop, P. S., Cisse, F., Ka, I., Deguenonvo, G. Ndiaye, A., Samba, S., Coly, NF.,… & Diallo, F. ’Thiam, “Clinical and biochemical profiles of TP53 codon 249 mutation in senegalese patients with hepatocellular carcinoma,” International Journal of Micro Biology, Genetics and Monocular Biology Research, vol. 5, no. 1, pp. 1–10, 2021.
[7]	Chevet, A. L., Couchy, G., Letouzé1, E., Calvo12, F., & Zucman-Rossi, J. Exome-sequencing identifies new oncogenes and tumor suppressor genes recurrently altered in hepatocellular carcinoma.
[8]	Fujimoto, A., Totoki, Y., Abe, T., Boroevich, K. A., Hosoda, F., Nguyen, H. H.,... & Nakagawa, H. (2012). Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature genetics, 44 (7), 760-764.
[9]	Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S.,... & Zucman-Rossi, J. (2015). Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature genetics, 47 (5), 505-511.
[10]	Colombino, M., Sperlongano, P., Izzo, F., Tatangelo, F., Botti, G., Lombardi, A.,... & Palmieri, G. (2012). BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell death & disease, 3 (1), e259-e259.
[11]	Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J. (2019). Molecular and histological correlations in liver cancer. Journal of hepatology, 71 (3), 616-630
[12]	Lozano, A. (2021). Hététogénéité intratumorale et dynamique des populations du carcinome hépatocellulaire: impact de l’intensité de la signalisation Ras/MAPK Erk (Doctoral dissertation, Université Montpellier).
[13]	Dorard, C., Vucak, G., & Baccarini, M. (2017). Deciphering the RAS/ERK pathway in vivo. Biochemical Society Transactions, 45 (1), 27-36.
[14]	IARC-Senegal Cancer, “https://gco.iarc.fr/today/data/factsheets/populations/686-senegal-fact-sheets.pdf.”
[15]	Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N.,... & Ferguson, M. L. (2017). Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell, 169 (7), 1327-1341.
[16]	Zuo, Q., Huang, H., Shi, M., Zhang, F., Sun, J., Bin, J.,... & Liao, W. (2012). Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology, 295 (3), 423-431.
[17]	Weihrauch, M., Benicke, M., Lehnert, G., Wittekind, C., Wrbitzky, R., & Tannapfel, A. (2001). Frequent k-ras-2 mutations and p16INK4Amethylation in hepatocellular carcinomas in workers exposed to vinyl chloride. British journal of cancer, 84 (7), 982-989.
[18]	Hou, W., Liu, J., Chen, P., Wang, H., Ye, B. C., & Qiang, F. (2014). Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncology letters, 8 (3), 1249-1254.
[19]	Marchoudi, N., Joutei, H. A. H., Jouali, F., Fekkak, J., & Rhaissi, H. (2013). Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Biologie, 61 (6), 273-276.
[20]	L. Pegah, G. Ehsan, T. Mohammad Yaghoob, K. Fatemeh, N. M. Ehsan, and A. Hamid Asadzadeh, “Coexistence of KRAS and BRAF mutations in colorectal cancer: a case report supporting the concept of tumoral heterogeneity,” pp. 113–117, 2017.
[21]	F. Diallo-Agne et al (2018), “Descriptive analysis of KRAS and BRAF mutations in senegalensis patients with colorectal cancer,” International Research Journal of Biochemestry and Bioinformatics, vol. 8, no. 3, pp. 1–10.
[22]	Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F.,... & Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. New England journal of medicine, 359 (4), 378-390.
[23]	“EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma.” [Online]. Available: http://cancer.gov/cancertopics/pdq/lev-.
[24]	Lee, S. J., Lee, J., Sohn, I., Mao, M. A. O., Kai, W., Park, C. K., & Lim, H. Y. (2013). A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer research, 33 (11), 5179-5186.
[25]	Gnoni, A., Licchetta, A., Memeo, R., Argentiero, A., Solimando, A. G., Longo, V.,... & Brunetti, O. (2019). Role of BRAF in hepatocellular carcinoma: a rationale for future targeted cancer therapies. Medicina, 55 (12), 754.
[26]	Kalinina, O., Marchio, A., Urbanskii, A. I., Tarkova, A. B., Rebbani, K., Granov, D. A.,... & Pineau, P. (2013). Somatic changes in primary liver cancer in Russia: A pilot study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 755 (2), 90-99.
[27]	Caraglia, M., Giuberti, G., Marra, M., Addeo, R., Montella, L., Murolo, M.,... & Stiuso, P. (2011). Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death & Disease, 2 (4), e150-e150.
[28]	“Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors - Full Text View - ClinicalTrials.gov.” https://www.clinicaltrials.gov/ct2/show/NCT03176485?term=Evaluation+of+Pathway+Modulation+by+Raf%2C+MEK%2C+%26+Kinase+Inhibitors&draw=2&rank=1 (accessed Jan. 21, 2022).
[29]	Wang, W., Xiao, Y., Li, S., Zhu, X., Meng, L., Song, C.,... & Liu, Y. (2019). Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway. American Journal of Translational Research, 11 (6), 3816.
[30]	Xiong, D., Song, Y. P., Xiong, W., & Liang, Y. D. (2015). An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk. Genet Mol Res, 14 (4), 14050-5.
[31]	Silva, S. D. C. (2018). Análise da expressão das proteínas KRAS, BRAF e MEK da via de sinalização intracelular mitogen activated protein kinases (MAPK) no carcinoma hepatocelular associado a hepatopatia crônica de diferentes etiologias.

Cite This Article

Plain Text BibTeX RIS

APA Style

Thiam Souleymane, Dia Fatou Kine Sy Thorpe, Sambiani Damigou Mawuli, Diop Papa Saloum, Ka Ibrahima, et al. (2022). KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal. International Journal of Genetics and Genomics, 10(1), 37-42. https://doi.org/10.11648/j.ijgg.20221001.16

Copy | Download

ACS Style

Thiam Souleymane; Dia Fatou Kine Sy Thorpe; Sambiani Damigou Mawuli; Diop Papa Saloum; Ka Ibrahima, et al. KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal. Int. J. Genet. Genomics 2022, 10(1), 37-42. doi: 10.11648/j.ijgg.20221001.16

Copy | Download

AMA Style

Thiam Souleymane, Dia Fatou Kine Sy Thorpe, Sambiani Damigou Mawuli, Diop Papa Saloum, Ka Ibrahima, et al. KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal. Int J Genet Genomics. 2022;10(1):37-42. doi: 10.11648/j.ijgg.20221001.16

Copy | Download

@article{10.11648/j.ijgg.20221001.16,
  author = {Thiam Souleymane and Dia Fatou Kine Sy Thorpe and Sambiani Damigou Mawuli and Diop Papa Saloum and Ka Ibrahima and Deguenonvo Gabriel Nougnignon Comlan and Ndiaye Yaye Dié and Cisse Fatou and Ndiaye Arame and Samba Abdourahmane and Coly Najah Fatou and Soumah Idrissa Yaya and Diedhiou Fatou and Agossou Hortence Honorine Médécé and Gaye Amy and Ndiaye Tolla and Dial Cherif Mouhame and Ndiaye Daouda and Diallo Fatou},
  title = {KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal},
  journal = {International Journal of Genetics and Genomics},
  volume = {10},
  number = {1},
  pages = {37-42},
  doi = {10.11648/j.ijgg.20221001.16},
  url = {https://doi.org/10.11648/j.ijgg.20221001.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20221001.16},
  abstract = {Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV is endemic. The objective of our study was to determine the prevalence of KRAS and BRAF mutations in patients with HCC. Mutations in codons 12 and 13 of KRAS and the V600E mutation of the BRAF gene were searched by HRM on Light Cycler 480 and confirmed by direct sequencing. A total of 34 HCC patients underwent molecular testing for codon 12 and 13 mutations in the KRAS gene and the V600E mutation in the BRAF gene. Melting curve analysis showed a prevalence of 23.5% (n=8/34) for the KRAS gene and 41.2% (n=14/34) for the BRAF gene. The mean age of BRAF mutation carriers was lower compared with KRAS mutation carriers. Chronic HBV carriage appeared to play a role in the development of these mutations, increasing the risk by 2 (CI(95)=0.55-7.24; p=0.395) for BRAF and by 1.78 (CI(95)=0.23-13.5; p=1) for KRAS. KRAS and BRAF mutations do not appear to play a role in tumor metastasis. However, these results need to be confirmed by further studies with a larger sample size. Alterations in the RAS/RAF/MAP Kinase pathway appear to be more prominent in HBV-induced HCC. This may hinder management with receptor tyrosine kinase inhibitors, the basis for treatment of advanced HCC.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal
AU  - Thiam Souleymane
AU  - Dia Fatou Kine Sy Thorpe
AU  - Sambiani Damigou Mawuli
AU  - Diop Papa Saloum
AU  - Ka Ibrahima
AU  - Deguenonvo Gabriel Nougnignon Comlan
AU  - Ndiaye Yaye Dié
AU  - Cisse Fatou
AU  - Ndiaye Arame
AU  - Samba Abdourahmane
AU  - Coly Najah Fatou
AU  - Soumah Idrissa Yaya
AU  - Diedhiou Fatou
AU  - Agossou Hortence Honorine Médécé
AU  - Gaye Amy
AU  - Ndiaye Tolla
AU  - Dial Cherif Mouhame
AU  - Ndiaye Daouda
AU  - Diallo Fatou
Y1  - 2022/03/09
PY  - 2022
N1  - https://doi.org/10.11648/j.ijgg.20221001.16
DO  - 10.11648/j.ijgg.20221001.16
T2  - International Journal of Genetics and Genomics
JF  - International Journal of Genetics and Genomics
JO  - International Journal of Genetics and Genomics
SP  - 37
EP  - 42
PB  - Science Publishing Group
SN  - 2376-7359
UR  - https://doi.org/10.11648/j.ijgg.20221001.16
AB  - Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV is endemic. The objective of our study was to determine the prevalence of KRAS and BRAF mutations in patients with HCC. Mutations in codons 12 and 13 of KRAS and the V600E mutation of the BRAF gene were searched by HRM on Light Cycler 480 and confirmed by direct sequencing. A total of 34 HCC patients underwent molecular testing for codon 12 and 13 mutations in the KRAS gene and the V600E mutation in the BRAF gene. Melting curve analysis showed a prevalence of 23.5% (n=8/34) for the KRAS gene and 41.2% (n=14/34) for the BRAF gene. The mean age of BRAF mutation carriers was lower compared with KRAS mutation carriers. Chronic HBV carriage appeared to play a role in the development of these mutations, increasing the risk by 2 (CI(95)=0.55-7.24; p=0.395) for BRAF and by 1.78 (CI(95)=0.23-13.5; p=1) for KRAS. KRAS and BRAF mutations do not appear to play a role in tumor metastasis. However, these results need to be confirmed by further studies with a larger sample size. Alterations in the RAS/RAF/MAP Kinase pathway appear to be more prominent in HBV-induced HCC. This may hinder management with receptor tyrosine kinase inhibitors, the basis for treatment of advanced HCC.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Thiam Souleymane

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Dia Fatou Kine Sy Thorpe

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Sambiani Damigou Mawuli

Surgical and Oncology Department, Sylvanus Olympio Hospital, Lome, Togo
Diop Papa Saloum

Surgical Department, General Hospital of Grand Yoff, Dakar, Senegal
Ka Ibrahima

Surgical Department, General Hospital of Grand Yoff, Dakar, Senegal
Deguenonvo Gabriel Nougnignon Comlan

Cytology and Pathology Department, General Hospital of Grand Yoff, Dakar, Senegal
Ndiaye Yaye Dié

International Centre for Research, Training in Applied Genomics and Health Surveillance, Cheikh Anta Diop University of Dakar, Dakar, Senegal
Cisse Fatou

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Ndiaye Arame

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Samba Abdourahmane

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Coly Najah Fatou

Pharmaceutical Biochemestry/Department of Medical Biology and Functional Exploration, Faculty of Health, Thies University, Thies, Senegal
Soumah Idrissa Yaya

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Diedhiou Fatou

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Agossou Hortence Honorine Médécé

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal
Gaye Amy

International Centre for Research, Training in Applied Genomics and Health Surveillance, Cheikh Anta Diop University of Dakar, Dakar, Senegal
Ndiaye Tolla

International Centre for Research, Training in Applied Genomics and Health Surveillance, Cheikh Anta Diop University of Dakar, Dakar, Senegal
Dial Cherif Mouhame

Cytology and Pathology Department, General Hospital of Grand Yoff, Dakar, Senegal
Ndiaye Daouda

International Centre for Research, Training in Applied Genomics and Health Surveillance, Cheikh Anta Diop University of Dakar, Dakar, Senegal
Diallo Fatou

Laboratory of Biochemistry and Molecular Biology, Faculty of Medicine, Cheikh Anta Diop University, Dakar, Senegal

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Thiam Souleymane, Dia Fatou Kine Sy Thorpe, Sambiani Damigou Mawuli, Diop Papa Saloum, Ka Ibrahima, et al. (2022). KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal. International Journal of Genetics and Genomics, 10(1), 37-42. https://doi.org/10.11648/j.ijgg.20221001.16

Copy | Download

ACS Style

Thiam Souleymane; Dia Fatou Kine Sy Thorpe; Sambiani Damigou Mawuli; Diop Papa Saloum; Ka Ibrahima, et al. KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal. Int. J. Genet. Genomics 2022, 10(1), 37-42. doi: 10.11648/j.ijgg.20221001.16

Copy | Download

AMA Style

Thiam Souleymane, Dia Fatou Kine Sy Thorpe, Sambiani Damigou Mawuli, Diop Papa Saloum, Ka Ibrahima, et al. KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal. Int J Genet Genomics. 2022;10(1):37-42. doi: 10.11648/j.ijgg.20221001.16

Copy | Download

@article{10.11648/j.ijgg.20221001.16,
  author = {Thiam Souleymane and Dia Fatou Kine Sy Thorpe and Sambiani Damigou Mawuli and Diop Papa Saloum and Ka Ibrahima and Deguenonvo Gabriel Nougnignon Comlan and Ndiaye Yaye Dié and Cisse Fatou and Ndiaye Arame and Samba Abdourahmane and Coly Najah Fatou and Soumah Idrissa Yaya and Diedhiou Fatou and Agossou Hortence Honorine Médécé and Gaye Amy and Ndiaye Tolla and Dial Cherif Mouhame and Ndiaye Daouda and Diallo Fatou},
  title = {KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal},
  journal = {International Journal of Genetics and Genomics},
  volume = {10},
  number = {1},
  pages = {37-42},
  doi = {10.11648/j.ijgg.20221001.16},
  url = {https://doi.org/10.11648/j.ijgg.20221001.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20221001.16},
  abstract = {Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV is endemic. The objective of our study was to determine the prevalence of KRAS and BRAF mutations in patients with HCC. Mutations in codons 12 and 13 of KRAS and the V600E mutation of the BRAF gene were searched by HRM on Light Cycler 480 and confirmed by direct sequencing. A total of 34 HCC patients underwent molecular testing for codon 12 and 13 mutations in the KRAS gene and the V600E mutation in the BRAF gene. Melting curve analysis showed a prevalence of 23.5% (n=8/34) for the KRAS gene and 41.2% (n=14/34) for the BRAF gene. The mean age of BRAF mutation carriers was lower compared with KRAS mutation carriers. Chronic HBV carriage appeared to play a role in the development of these mutations, increasing the risk by 2 (CI(95)=0.55-7.24; p=0.395) for BRAF and by 1.78 (CI(95)=0.23-13.5; p=1) for KRAS. KRAS and BRAF mutations do not appear to play a role in tumor metastasis. However, these results need to be confirmed by further studies with a larger sample size. Alterations in the RAS/RAF/MAP Kinase pathway appear to be more prominent in HBV-induced HCC. This may hinder management with receptor tyrosine kinase inhibitors, the basis for treatment of advanced HCC.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - KRAS and BRAF Mutations in Patients with Hepatocellular Carcinoma in Senegal
AU  - Thiam Souleymane
AU  - Dia Fatou Kine Sy Thorpe
AU  - Sambiani Damigou Mawuli
AU  - Diop Papa Saloum
AU  - Ka Ibrahima
AU  - Deguenonvo Gabriel Nougnignon Comlan
AU  - Ndiaye Yaye Dié
AU  - Cisse Fatou
AU  - Ndiaye Arame
AU  - Samba Abdourahmane
AU  - Coly Najah Fatou
AU  - Soumah Idrissa Yaya
AU  - Diedhiou Fatou
AU  - Agossou Hortence Honorine Médécé
AU  - Gaye Amy
AU  - Ndiaye Tolla
AU  - Dial Cherif Mouhame
AU  - Ndiaye Daouda
AU  - Diallo Fatou
Y1  - 2022/03/09
PY  - 2022
N1  - https://doi.org/10.11648/j.ijgg.20221001.16
DO  - 10.11648/j.ijgg.20221001.16
T2  - International Journal of Genetics and Genomics
JF  - International Journal of Genetics and Genomics
JO  - International Journal of Genetics and Genomics
SP  - 37
EP  - 42
PB  - Science Publishing Group
SN  - 2376-7359
UR  - https://doi.org/10.11648/j.ijgg.20221001.16
AB  - Hepatocellular carcinoma (HCC) is a public health problem in developing countries where chronic HBV is endemic. The objective of our study was to determine the prevalence of KRAS and BRAF mutations in patients with HCC. Mutations in codons 12 and 13 of KRAS and the V600E mutation of the BRAF gene were searched by HRM on Light Cycler 480 and confirmed by direct sequencing. A total of 34 HCC patients underwent molecular testing for codon 12 and 13 mutations in the KRAS gene and the V600E mutation in the BRAF gene. Melting curve analysis showed a prevalence of 23.5% (n=8/34) for the KRAS gene and 41.2% (n=14/34) for the BRAF gene. The mean age of BRAF mutation carriers was lower compared with KRAS mutation carriers. Chronic HBV carriage appeared to play a role in the development of these mutations, increasing the risk by 2 (CI(95)=0.55-7.24; p=0.395) for BRAF and by 1.78 (CI(95)=0.23-13.5; p=1) for KRAS. KRAS and BRAF mutations do not appear to play a role in tumor metastasis. However, these results need to be confirmed by further studies with a larger sample size. Alterations in the RAS/RAF/MAP Kinase pathway appear to be more prominent in HBV-induced HCC. This may hinder management with receptor tyrosine kinase inhibitors, the basis for treatment of advanced HCC.
VL  - 10
IS  - 1
ER  -

Copy | Download